Business Context and Reporting Period
This Form 8-K was filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc.) on March 14, 2023. The filing serves to announce the results of operations for the fourth quarter and full year ended December 31, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K summary.
Material Changes
No material changes or comparative financial data are detailed within the body of this filing. The document acts solely as a notification that the Q4 and full-year 2022 results have been issued.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk disclosures regarding the 2022 results. It includes a standard disclaimer stating that the information furnished pursuant to Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities under that section.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc. (VIRI), as the request metadata incorrectly listed Dogwood Therapeutics.
- Review Exhibit 99.1 (the Press Release dated March 14, 2023) to obtain actual financial figures for Q4 and full-year 2022.
- Confirm the company's status as an emerging growth company (indicated by a checkmark in the filing).
- Note that the financial data in this 8-K is furnished, not filed, limiting its legal liability under Section 18 of the Exchange Act.